Tumorigenesis is a multistep process that results from the sequential accumulation of mutations in key oncogene and tumour suppressor pathways. Personalized cancer therapy that is based on targeting these underlying genetic abnormalities presupposes that sustained inactivation of tumour suppressors and activation of oncogenes is essential in advanced cancers. Mutations in the p53 tumoursuppressor pathway are common in human cancer and significant efforts towards pharmaceutical reactivation of defective p53 pathways are underway [1] [2] [3] . Here we show that restoration of p53 in established murine lung tumours leads to significant but incomplete tumour cell loss specifically in malignant adenocarcinomas, but not in adenomas. We define amplification of MAPK signalling as a critical determinant of malignant progression and also a stimulator of Arf tumour-suppressor expression. The response to p53 restoration in this context is critically dependent on the expression of Arf. We propose that p53 not only limits malignant progression by suppressing the acquisition of alterations that lead to tumour progression, but also, in the context of p53 restoration, responds to increased oncogenic signalling to mediate tumour regression. Our observations also underscore that the p53 pathway is not engaged by low levels of oncogene activity that are sufficient for early stages of lung tumour development. These data suggest that restoration of pathways important in tumour progression, as opposed to initiation, may lead to incomplete tumour regression due to the stage-heterogeneity of tumour cell populations.
Experimental restoration of p53 (also known as Trp53) tumoursuppressor function has highlighted the potential for therapeutic intervention of this pathway to treat cancer and has uncovered a diversity of anti-tumour responses in different tumour types [4] [5] [6] . These studies imply that some types of cancer rely upon sustained inactivation of the p53 pathway as these tumours undergo rapid, and sometimes complete, regression once p53 is restored. To elucidate the role of p53 in lung cancer progression and to evaluate the therapeutic potential of p53 reactivation in this disease, we analysed the effect of Trp53 restoration in a mouse model of Kras G12D -driven lung cancer at different time points in tumour progression. Trp53 restoration was achieved by delivering tamoxifen to 4-week-old Kras LA2/1 ;Trp53 LSL/LSL ;Rosa26 CreERT2 mice ( Supplementary Fig. 1 ). We measured tumour volumes with microcomputed tomography and tumour areas by histological analysis. Surprisingly, at this time point, Trp53 restoration did not significantly change tumour size or number ( Fig. 1a, b ). Efficient deletion of the 'STOP' element from Trp53 LSL alleles was evident in all tumours analysed ( Supplementary Fig. 2 ).
To establish the timing and stage of tumour progression when the effects of p53 mutation are evident, we compared Kras LA2/1 ;Trp53 LSL/LSL tumours to tumours from age-matched Kras LA2/1 ;Trp53 1/1 mice. At four weeks, most tumours were adenomatous hyperplasias or alveolar adenomas with monomorphous epithelial cells and uniform nuclei ( Supplementary Fig. 3 ). In Kras LA2/1 ;Trp53 LSL/LSL mice at this age, a small fraction of tumours had mixed histological features with focal areas of adenocarcinoma within lower grade lesions ( Fig. 1c ). Although most tumours in Kras LA2/1 ;Trp53 1/1 and Kras LA2/1 ;Trp53 LSL/LSL mice were of similar grade, the presence of pleomorphic nuclei was a prominent feature of Kras LA2/1 ;Trp53 LSL/LSL tumours compared to Kras LA2/1 ;Trp53 1/1 tumours (Fig. 1d that Kras LA2/1 ;Trp53 LSL/LSL tumour cells have a higher degree of genetic instability that may facilitate tumour progression at a later time point. At 10 weeks of age, Kras LA2/1 ;Trp53 LSL/LSL tumours were much more likely to exhibit nuclear pleomorphism and regions of advanced histopathology. Beyond these mixed grade tumours, frank adenocarcinomas were present exclusively in Kras LA2/1 ;Trp53 LSL/LSL mice ( Fig. 1c) . Given that high-grade tumours were more prevalent in older mice, we restored Trp53 in 10-week-old Kras LA2/1 ;Trp53 LSL/LSL ;Rosa26 CreERT2 mice. Here, restoration of Trp53 resulted in significantly smaller tumours compared to controls after 2 weeks ( Fig. 1e, f) . To monitor the response of individual tumours, we performed serial micro-computed tomography before and after Trp53 restoration. Although control tumours continued to grow during the 2-week time course, we found that the average size of tumours after Trp53 restoration was static ( Fig. 1g ). However, the response of individual tumours was variable ( Supplementary Fig. 4 ). Thus, we proposed that only a subset of tumours is sensitive to Trp53 restoration.
Upon Trp53 restoration, adenocarcinomas, but not adenomas, displayed multiple features of cellular senescence. Both p53 and the p53 target gene Cdkn1a (also known as p21) were detectable in tumours as early as 3 days after restoration, but were specifically confined to tumours with adenocarcinomatous features ( Fig. 2b and Supplementary Fig. 5 ). In addition to observing p21 induction in the adenocarcinomas of 10-week-old mice ( Fig. 2c ), p21 was also induced in the few carcinomas found in the 4-week-old animals (data not shown). Moreover, Trp53 restoration caused reduced cellular proliferation ( Fig. 2d ). Of note, the percentage of tumours with adenocarcinomatous features was significantly diminished 2 weeks after Trp53 restoration with many tumours showing gaps between collections of low-grade tumour cells filled with foam macrophages ( Fig. 2a, e ). Despite this evidence of cell loss, we failed to find signs of apoptosis in lung tumours across an extensive time course after Trp53 restoration ( Supplementary Fig. 6 ). Collectively, these data demonstrate that adenomas do not respond to p53 restoration, whereas adenocarcinomas are sensitive. Moreover, Trp53 mutation per se does not induce phenotypic changes in tumour grade but rather creates a permissive environment for the outgrowth of cells that have undergone additional steps in tumour progression. Finally, the alterations that drive tumour progression can also stimulate p53-dependent cellular responses.
To interrogate the mechanisms that drive tumour progression, we performed immunohistochemistry on tumours from Kras LA2/1 ;Trp53 1/1 and Kras LA2/1 ;Trp53 LSL/LSL animals to assess the activity of multiple relevant pathways during the adenoma-adenocarcinoma transition. We found that phosphorylation levels of Mek1/2 (p-Mek, also known as Map2k1/2) and p42/p44 MAPK (p-Erk, also known as Mapk1) was markedly higher in adenocarcinomas compared to adenomas ( Fig. 3a,  b ). This observation indicated that amplified MAPK signalling could drive progression of Kras G12D -initiated lung cancer. High levels of MAPK signalling downstream of oncogenic Kras induces cell cycle arrest/senescence mediated by Arf (a product of the Cdkn2a locus) and p53 in multiple cell types in vitro [7] [8] [9] . In contrast, physiological levels of oncogenic signalling elicited by a single oncogenic Kras allele do not activate the Arf/p53 tumour suppressor pathway and instead can drive proliferation and tumorigenesis in many cell types [10] [11] [12] [13] [14] . Some cancer models show that mutation of Ras family members can initiate tumorigenesis, while amplification of oncogenic Ras or loss of the wildtype Ras allele is associated with tumour progression [15] [16] [17] . Thus, we proposed that amplification of oncogenic signalling could simultaneously drive tumour progression and the outgrowth of cells that had inactivated the p53 pathway during the natural course of tumour evolution. Consistent with this hypothesis, fluorescent in situ hybridization (FISH) analysis showed that a subset of adenocarcinomas with high p-Erk had copy number gains of the Kras locus. Conversely, copy number alterations of Kras were never seen in adenomas (Fig. 3c ). Together, these observations indicate that although the mechanisms that amplify oncogenic signalling are likely to be diverse, MAPK signal amplification typifies Kras LA2 lung adenocarcinomas and may drive progression towards malignancy.
To test whether cells with amplified MAPK signalling persist after Trp53 restoration, we analysed Kras LA2/1 ;Trp53 LSL/LSL ;Rosa26 CreERT2 animals across a time course after tamoxifen administration. Loss of high p-Erk staining cells was evident 1 week after Trp53 restoration (Supplementary Fig. 7 ). Compared to controls, tumours with Trp53 restored showed significantly fewer p-Erk positive tumours after 2 weeks (Fig. 3d ). This observation, in conjunction with the selective loss of histologically advanced tumour cells seen after Trp53 restoration, suggests that amplified MAPK signalling is incompatible with p53 expression.
Next, we micro-dissected tumours from Kras LA2/1 ;Trp53 LSL/LSL mice and performed gene expression analysis to characterize better the molecular alterations that drive tumour progression. We developed an 'adenocarcinoma signature' by comparing the gene expression profiles of adenocarcinomas and adenomas (Fig. 4a ). Gene set enrichment analysis showed that pathways associated with increased proliferation such as cell cycle processes, the Ras pathway and c-myc (also known as Myc) target genes were enriched in adenocarcinomas compared to adenomas (Fig. 4b) . Other gene sets associated with adenocarcinomas were chemokine regulation, inflammation and immune responses, as 
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well as AP1 and PEA3 (also known as Jun and Etv4, respectively) target genes. These data indicate that multiple pathways are enhanced upon progression to malignancy coincident with, or as a result of, amplified MAPK signalling.
To assess the response to p53 restoration in adenocarcinomas at the level of gene expression, we profiled micro-dissected tumours from Kras LA2/1 ;Trp53 LSL/LSL ;Rosa26 CreERT2 mice seven days after Trp53 restoration. Each tumour was histologically analysed for evidence consistent with a p53 response and the appearance of some adenocarcinoma features ( Supplementary Fig. 7 ). We used the adenocarcinoma signature to perform hierarchical clustering on these p53-restored samples together with adenomas and adenocarcinomas. Interestingly, the p53-restored samples clustered with adenomas with high confidence. Additionally, adenocarcinoma specific gene sets were deenriched in Trp53-restored tumours (Fig. 4a, b) . These data are consistent with our observation that adenocarcinoma cells are specifically culled from these tumours leaving behind adenoma cells that are unresponsive to p53 restoration.
Hyperactive MAPK signalling has been shown to induce the transcription of Cdkn2a, leading to expression of Arf, an upstream activator of p53 (ref. 9). Consistent with this mechanism of triggering the p53 pathway, we found that Cdkn2a expression was higher in adenocarcinomas compared to adenomas ( Supplementary Fig. 8a ). Moreover, in tumours from Kras LA2/1 ;Trp53 LSL/LSL mice, p-Erk co-localizes with Arf staining by immunofluorescence and immunohistochemistry specifically in adenocarcinomas and the higher-grade areas of mixed-grade tumours ( Fig. 4c and Supplementary Fig. 8b, c) . To test the functional requirement of Arf in the p53 response, we studied cell lines generated from Kras LA2/1 ;Trp53 LSL/LSL ;Rosa26 CreERT2 lung adenocarcinomas. As we had observed in vivo, restoration of Trp53 in cell culture led to prolonged cell cycle arrest without appreciable cell death. Further, the gene expression program elicited by Trp53 restoration in these cell lines is similar to that observed in vivo, validating them as a relevant model with which to test Arf dependency for activation of p53 responses after Trp53 restoration ( Supplementary Fig. 9 ). We expressed shRNAs (short hairpin RNAs) targeted against either an Arf-specific 
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transcript of Cdkn2a or Trp53 in cell lines before Trp53 restoration. As shown in Fig. 4d , inhibition of Arf or p53 allowed cells to continue to proliferate following addition of tamoxifen. Furthermore, Arf knockdown kept p53 levels low after Trp53 restoration and limited the induction of the p53 target gene p21 ( Fig. 4e and Supplementary Fig. 9c ).
These data indicate that Arf is required for p53 restoration-induced cell cycle arrest in this system. Our failure to detect apoptosis following Trp53 restoration stands in contrast to a report published together with ours in this issue 18 . The most likely explanation for this discrepancy is the different technologies used to control p53 function. Whereas our method restores a disrupted gene back to its wild-type state and allows otherwise normal p53 expression, our colleagues used a p53-ER fusion protein that might be expected to accumulate to high levels in advanced tumours that express Arf 18 . Thus, in that setting, p53-ER may induce more robust responses that include apoptosis when activated by tamoxifen.
Given our results on the requirement of Arf in the p53 response in this setting, one might imagine that Arf and p53 mutations would have equivalent effects in lung cancer progression. However, unlike in Kras LA2/1 ;Trp53 LSL/LSL mice, carcinomas rarely develop in Kras LA2 mice carrying Arf mutations 19 . Thus, the clear effects of p53 mutation on tumour progression are likely to reflect additional functions of p53, including its role in responding to DNA damage and other forms of genomic instability 20 .
The possibility that reactivation of defective p53 pathways will lead to variable and incomplete tumour regression is intriguing and may have important implications for anti-cancer therapies. As a tumour naturally progresses, multiple related, but genetically distinct clones co-evolve within the tumour. Conceptually akin to resistance mutations that are selected after targeted cancer therapies, pharmacological targeting of mutations that drive tumour progression, rather than initiation, may lead to significant pruning of some clones but leave behind others that still have significant potential to progress further in tumorigenesis. Although it is generally accepted that the elimination of the most advanced tumour cells within a cancer will be a significant benefit in cancer therapy, strategies to eliminate, or prevent progression of, the less advanced residual tumour cells may be important to allow durable therapeutic responses.
METHODS SUMMARY
Mice. Animal studies were approved by the Committee for Animal Care, and conducted in compliance with the Animal Welfare Act Regulations and other federal statutes relating to animals and experiments involving animals and adheres to the principles set forth in the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996 (institutional animal welfare assurance no. A-3125-01). All animals were maintained on a mixed C57BL/6J x 129SvJ strain. Tamoxifen (Sigma) was administered intraperitoneally twice weekly at 200 mg per gram total body weight. Micro-computed tomography analysis was performed as described 21 . Histology and immunohistochemistry. Formalin-fixed paraffin-embedded sections were stained with antibodies against p53 (Novocastra NCL-p53-CM5p), phosphorylated Mek1/2 (p-Mek), phosphorylated p42/p44 MAPK (p-Erk), cleaved caspase 3 (CC3), phosphorylated histone H3 (pH3) (Cell Signaling Technology), p19/Arf, or p21 (F5) (Santa Cruz Biotech). Immunofluorescence images were produced with a Delta Vision deconvolution microscope (Applied Precision) and SoftWorx software. Terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) staining was performed following the manufacturer's instructions (In situ Cell Death Detection kit, Roche). FISH was performed with Texas Redlabelled bacterial artificial chromosome (BAC) clone RP23-188E5. Gene expression analysis. RNA was extracted from micro-dissected tumours using TRIzol (Invitrogen). RNA was processed, labelled and hybridized to Affymetrix 430A_v2 chips. Gene expression data was deposited in Gene Expression Omnibus (GSE23875). Cell lines. Cell lines were derived from Kras LA2/1 ;Trp53 LSL/LSL ;Rosa26 CreERT2 adenocarcinomas. Retroviruses expressing shRNAs were designed and cloned as described previously 22 . Cell cycle analysis was performed according to the APC BrdU Flow Kit (BD Parmingen). Immunoblot analysis. p53 protein was detected using NCL-p53-505 (Novocastra), Hsp90 served as a loading control and was detected using a monoclonal antibody (BD Transduction Laboratories). Other antibodies were as for immunohistochemistry.
